Overview

Atralin Gel for the Treatment of Rosacea

Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR).
Phase:
Phase 3
Details
Lead Sponsor:
Lisa E. Maier
Collaborators:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Tretinoin